GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it says could become one of the largest in Europe. The drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback